Actinium Pharmaceuticals Inc. (ATNM) Downgraded by Zacks Investment Research
Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
ATNM has been the subject of a number of other research reports. FBR & Co reaffirmed a “buy” rating on shares of Actinium Pharmaceuticals in a research report on Thursday, June 30th. Roth Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Wednesday, September 28th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/actinium-pharmaceuticals-inc-atnm-downgraded-by-zacks-investment-research.html
Shares of Actinium Pharmaceuticals (NYSEMKT:ATNM) traded down 3.97% during midday trading on Tuesday, reaching $1.16. The company’s stock had a trading volume of 949,560 shares. Actinium Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $3.50. The stock’s market cap is $55.35 million. The stock has a 50-day moving average price of $1.64 and a 200-day moving average price of $1.77.
In related news, major shareholder Sloan-Kettering Cance Memorial sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $1.71, for a total transaction of $85,500.00. Following the completion of the transaction, the insider now owns 4,939,490 shares of the company’s stock, valued at approximately $8,446,527.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Institutional Trust Company N.A. increased its stake in shares of Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock valued at $819,000 after buying an additional 47,131 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of Actinium Pharmaceuticals by 31.5% in the second quarter. BlackRock Fund Advisors now owns 102,003 shares of the company’s stock valued at $181,000 after buying an additional 24,453 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock valued at $2,798,000 after buying an additional 254,318 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at approximately $247,000.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.